A PHASE I STUDY OF AN EGFRVIII PEPTIDE-BASED VACCINE IN PATIENTS WITH CANCER

基于 EGFRVIII 肽的疫苗对癌症患者的 I 期研究

• 批准号: 7379316
• 负责人: Bruce Montgomery
• 金额: $ 1.08万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7379316
• 关键词: PHASE; STUDY; EGFRVIII; PEPTIDE; BASED

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a study funded by the National Cancer Institute to study the safety and immunologic efficacy of the EGFRvIII peptide vaccine in patients whose tumors express the tumor specific antigen EGFRvIII and who are at high risk for relapse or progression of their cancer. This includes patients with ovarian, prostate and stomach cancers. The peptide vaccine will be administered with GM-CSF or KLH as adjuvant in order to: 1) evaluate the safety and define the potential toxicity of immunizing patients with an EGFRvIII based peptide vaccine; 2) determine the level of EGFR specific antibody response after immunization with EGFRvIII peptide; and 3) determine the level of EGFR specific T cell response after immunization with EGFRvIII peptide.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这是一项由美国国家癌症研究所资助的研究，旨在研究EGFRvIII肽疫苗在肿瘤表达肿瘤特异性抗原EGFRvIII且癌症复发或进展风险高的患者中的安全性和免疫学疗效。这包括卵巢癌、前列腺癌和胃癌患者。肽疫苗将与作为佐剂的GM-CSF或KLH一起施用，以：1）评价用基于EGFRvIII的肽疫苗免疫患者的安全性并确定其潜在毒性; 2）确定用EGFRvIII肽免疫后EGFR特异性抗体应答的水平;和3）确定用EGFRvIII肽免疫后EGFR特异性T细胞应答的水平。